Neuroendocrine Liver Metastases

Surgical Clinics of North America

Volumn 90, Issue 4, 2010, Pages 853-861

  Reddy, Srinevas K ^a   Clary, Bryan M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Ablation; Chemotherapy; Hepatic arterial infusion; Liver transplantation; Neuroendocrine liver metastases; Resection

Indexed keywords

CYANOACRYLATE; GELFOAM; MICROSPHERE; POLYVINYL ALCOHOL; ANTINEOPLASTIC AGENT;

ARTIFICIAL EMBOLISM; CHEMOEMBOLIZATION; HEPATIC ARTERY; HUMAN; LIVER METASTASIS; LIVER RESECTION; LIVER TRANSPLANTATION; NEUROENDOCRINE LIVER METASTASIS; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SURGICAL TECHNIQUE; SURVIVAL TIME; CATHETER ABLATION; INTRAARTERIAL DRUG ADMINISTRATION; LIVER NEOPLASMS; NEUROENDOCRINE TUMORS; PROCEDURES; SECONDARY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CATHETER ABLATION; HEPATECTOMY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEUROENDOCRINE TUMORS; TREATMENT OUTCOME;

EID: 77954626025     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2010.04.016     Document Type: Review

References (39)

1. Vogl T.J., Naguib N.N., Zangos S., et al. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization, and thermal ablation. Eur J Radiol 2009, 72:517-528.
2. Clary B. Treatment of isolated neuroendocrine liver metastases. J Gastrointest Surg 2006, 10:332-334.
3. 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. Surgery 2004, 136:1218-1226.
4. Faiss S., Pape U.F., Bohmig M., et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003, 21:2689-2696.
5. Sung W., Lipsitz S., Catalano P., et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group study E1281. J Clin Oncol 2005, 23:4897-4904.
6. Fjallskog M.H., Granberg D.P.K., Welin S.L.V., et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001, 92:1101-1107.
7. Ishe I., Persson B., Tibblin S. Neuroendocrine metastases of the liver. World J Surg 1995, 19:76-82.
8. Guruswamy K.S., Ramamoorthy R., Sharma D., et al. Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev 2009, 2:CD007060. 10.1002/14651858.CD007060.pub2.
9. Guruswamy K.S., Pamecha V., Sharma D., et al. Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Cochrane Database Syst Rev 2009, 1:CD007118. 10.1002/14651858.CD007118.pub2.
10. Reddy S.K., Barbas A.S., Marroquin C.E., et al. Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis. J Am Coll Surg 2007, 204:372-382.
11. Touzios J.G., Kiely J.M., Pitt S.C., et al. Neuroendocrine hepatic metastases: does aggressive management improve survival?. Ann Surg 2005, 241:776-785.
12. Sarmiento J.M., Heywood G., Rubin J., et al. Surgical treatment of neuroendocrine metastases to liver: a plea for resection to increase survival. J Am Coll Surg 2003, 197:29-37.
13. Chen H., Hardacre J.M., Uzar A., et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?. J Am Coll Surg 1998, 187:88-93.
14. Osborne D.A., Zervos E.E., Strosberg J., et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 2006, 13:572-581.
15. Landry C.S., Scoggins C.R., McMasters K.M., et al. Management of hepatic metastasis of gastrointestinal carcinoid tumors. J Surg Oncol 2008, 97:253-258.
16. Yao K.A., Talamonti M.S., Nemcek A., et al. Indications and results liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 2001, 130:677-685.
17. Chamberlain R.S., Canes D., Brown K.T., et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg 2000, 190:432-445.
18. Sutcliffe R., Maguire D., Ramage J., et al. Management of neuroendocrine liver metastases. Am J Surg 2004, 187:39-46.
19. Sarmiento J.M., Que F.G. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 2003, 12:231-242.
20. Que F.G., Nagorney D.M., Batts K.P., et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995, 169:36-42.
21. Mazzaglia P.J., Berber E., Milas M., et al. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 2007, 142:10-19.
22. Gilliams A., Cassoni A., Conway G., et al. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging 2005, 30:435-441.
23. Elvin A., Skogseid B., Hellman P. Radiofrequency ablation of neuroendocrine liver metastases. Abdom Imaging 2005, 30:427-434.
24. Chung M.H., Pisegna J., Spirt M., et al. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 2001, 130:954-962.
25. Kolby L., Persson G., Franzen S., et al. Randomized clinical trial of the effect of interferon α on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 2003, 90:687-693.
26. Pitt S.C., Knuth J., Keily J.M., et al. Hepatic neuroendocrine metastases: chemo- or bland embolization?. J Gastrointest Surg 2008, 12:1951-1960.
27. Gupta S., Johnson M.M., Murthy R., et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors. Cancer 2005, 104:1590-1602.
28. Vogl T.J., Gruber T., Naguib N.N., et al. Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols. AJR Am J Roentgenol 2009, 193:941-947.
29. Sward C., Johanson V., Dijkum Nieveen van, et al. Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome. Br J Surg 2009, 96:517-521.
30. Christante D., Pommier S., Givi B., et al. Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy. Surgery 2008, 144:885-894.
31. Strosberg J.R., Choi J., Cantor A.B., et al. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control 2006, 13:72-78.
32. Ho A.S., Picus J., Darcy M.D., et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol 2007, 188:1201-1207.
33. Rosenau J., Bahr M., von Wasielewski R., et al. Ki67, E-Cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation 2002, 73:386-394.
34. Lang H., Schlitt H.J., Schmidt H., et al. Total hepatectomy and liver transplantation for metastatic neuroendocrine tumors of the pancreas-a single center experience with ten patients. Langenbecks Arch Surg 1999, 384:370-377.
35. Le Treut Y.P., Delpero J.R., Dousset B., et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors: a 31-case French multicentric report. Ann Surg 1997, 225:355-364.
36. van Vilsteren F.G.I., Baskin-Bey E.S., Nagorney D.M., et al. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transpl 2006, 12:448-456.
37. Florman S., Toure B., Kim L., et al. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg 2004, 8:208-212.
38. Routley D., Ramage J.K., McPeake J., et al. Orthotopic liver transplantation in the treatment of metastatic neuroendocrine tumors of the liver. Liver Transpl Surg 1995, 1:118-121.
39. Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation 1998, 66:1307-1312.